The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical

The Cancer Letter wins investigative, design awards

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The Cancer Letter won four 2019 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists:

  • Investigative Journalism, Newsletter/Trade Publications, first place, for “When Surgical Innovation Kills,” by Matthew Ong
  • Front Page Design, Newsletter/Trade Publications, first place, by Jacqueline Ong and Katherine Goldberg
  • Photo Illustration, Newsletter/Trade Publications, first place, by Katherine Goldberg
  • Series, Newsletter/Trade Publications, finalist, for “From Rhetoric to Harm,” by Paul Goldberg and Matthew Ong

Ong has won six Dateline Awards over the past five years. This is the third time Ong has won a first-place Dateline Award for his investigative work on minimally invasive surgery and cancer-related outcomes.

Ong’s series has also received awards from six organizations, including the National Press Club, the national Society of Professional Journalists, and the National Institute for Health Care Management (The Cancer Letter, How Medical Devices do Harm, 2014-2017; When Surgical Innovation Kills, 2018-2019).

This is the second consecutive year The Cancer Letter has won first-place design awards.

Here are a few of The Cancer Letter’s award-winning covers published in 2018:

TCL44-43 copy
TCL44-30 copy
TCL44-06 copy
TCL44-16 copy
TCL44-28 copy
Table of Contents

YOU MAY BE INTERESTED IN

Book Review

What are The CheckPoints movin’ and groovin’ to this summer?
Join the journal club with the best bops: We asked SITC’s 13-piece band of medical musicians for the top papers and songs of the summer

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.
By Sara Willa Ernst and Paul Goldberg
Guest Editorial

The defining question of the next decade is not how many drug candidates can be generated, but who decides which ones move forward, and why
Drug development must convene a forum for candid, cross-sector discussion

At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
By Richard L. Schilsky, H. Kim Lyerly, Thomas R. Fleming and Renzo Canetta
ClinicalGuest Editorial

Like it or not, AI psycho-oncology care is already happening. Urgently needed: An ethical framework
Developers and mental health providers must share the same goal: Safe, equitable, trustworthy, and patient-centered care

In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 
By Viktor Clark, Sean M. Dozier, AnnaLynn M. Williams, Cynthia M. Rand and Lee A. Kehoe
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account